Courtwright Andrew M, Baldi Bruno G, Kidambi Pranav, Cui Ye, Lamattina Anthony M, Villalba Julian A, Bagwe Shefali, Goldberg Hilary J, Rosas Ivan O, Henske Elizabeth Petri, Carvalho Carlos R R, El-Chemaly Souheil
Division of Pulmonary and Critical Care Medicine, Hospital of the University of Pennsylvania, PA, USA.
Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, MA, USA.
Sarcoidosis Vasc Diffuse Lung Dis. 2018;35(3):206-212. doi: 10.36141/svdld.v35i3.6321. Epub 2018 Apr 28.
A subset of lymphangioleiomyomatosis (LAM) patients present with normal FEV1 and FVC but with reduced DLCO. Patients with an isolated reduction in DLCO in other diseases appear to be at higher risk for pulmonary hypertension and worse survival but this has not been previously described in LAM patients. To characterize the prevalence and clinical progression of LAM patients who present with discordantly low DLCO. This was a retrospective cohort study of LAM patients in two centers in the United States and Brazil. Discordant DLCO was defined as FEV1 >80% predicted, FVC >80% predicted, and DLCO<80% predicted. We compared the rate of decline in pulmonary function, pulmonary artery to aorta (PA-A) ratio, and VEGF-D levels in patients with concordant and discordant DLCO. The overall prevalence of discordant DLCO was 26.0%. Patients with discordant DLCO did not have a higher rate of yearly decline in FEV1 (-1.0±0.6 vs -1.0±0.6, p=0.50), FVC (-1.0±0.7 vs -0.3±0.8, p=0.54), or DLCO (-2.2±0.9 vs -1.6±0.6, p=0.79). They did not have higher rates of PA-A ratio>1 (23.3% vs 20.1%, p=1.00). Patients with discordant DLCO did not have higher levels of VEGF-D (1214±1256 pg/mL vs 1706±1214 pg/mL, p=0.07). LAM patients who present with a discordantly low DLCO do not appear to have different rates of decline in pulmonary function. Additional biological and radiographic markers are needed to more fully characterize this population. .
一部分淋巴管平滑肌瘤病(LAM)患者的第一秒用力呼气容积(FEV1)和用力肺活量(FVC)正常,但一氧化碳弥散量(DLCO)降低。其他疾病中单纯DLCO降低的患者发生肺动脉高压的风险更高,生存率更低,但此前尚未在LAM患者中描述过这种情况。为了描述DLCO异常降低的LAM患者的患病率和临床进展情况。这是一项在美国和巴西两个中心对LAM患者进行的回顾性队列研究。DLCO异常定义为FEV1>预测值的80%,FVC>预测值的80%,且DLCO<预测值的80%。我们比较了DLCO正常和异常的患者肺功能下降率、肺动脉与主动脉比值(PA-A)以及血管内皮生长因子D(VEGF-D)水平。DLCO异常的总体患病率为26.0%。DLCO异常的患者FEV1的年下降率(-1.0±0.6 vs -1.0±0.6,p=0.50)、FVC的年下降率(-1.0±0.7 vs -0.3±0.8,p=0.54)或DLCO的年下降率(-2.2±0.9 vs -1.6±0.6,p=0.79)均无更高。他们PA-A比值>1的发生率也没有更高(23.3% vs 20.1%,p=1.00)。DLCO异常的患者VEGF-D水平也没有更高(1214±1256 pg/mL vs 1706±1214 pg/mL,p=0.07)。DLCO异常降低的LAM患者肺功能下降率似乎没有差异。需要更多的生物学和影像学标志物来更全面地描述这一人群。